Hydroxychloroquine and COVID-19: critiquing the impact of disease public profile on policy and clinical decision-making
The controversy surrounding the use of hydroxychloroquine (HCQ), an antimalarial drug, for COVID-19 has raised numerous ethical and policy problems. Since the suggestion that HCQ has potential for COVID-19, there have been varying responses from clinicians and healthcare institutions, ranging from a...
Authors: | ; |
---|---|
Format: | Electronic Article |
Language: | English |
Check availability: | HBZ Gateway |
Journals Online & Print: | |
Fernleihe: | Fernleihe für die Fachinformationsdienste |
Published: |
BMJ Publ.
2020
|
In: |
Journal of medical ethics
Year: 2020, Volume: 46, Issue: 9, Pages: 574-578 |
Online Access: |
Volltext (kostenfrei) Volltext (kostenfrei) |